Efficacy of EsoGuard on Samples Collected Using EsoCheck Versus EGD for the Diagnosis of BE (ESOGUARDBE1)
A Multicenter, Single-Arm Study of the Efficacy of EsoGuard(TM) on Samples Collected Using EsoCheck(TM) Versus Esophagogastroduodenoscopy for the Diagnosis of Barrett's Esophagus in an At-Risk Screening Population
Sponsor: Lucid Diagnostics, Inc.
Listed as NCT04293458, this NA trial focuses on Barrett Esophagus and Barrett's Esophagus Without Dysplasia and remains completed. Sponsored by Lucid Diagnostics, Inc., it has been updated 11 times since 2020, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Feb 2023 — Jul 2024 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Sep 2022 — Feb 2023 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Sep 2021 — Sep 2022 [monthly]
Recruiting NA
▶ Show 6 earlier versions
-
May 2021 — Sep 2021 [monthly]
Recruiting NA
-
Jan 2021 — May 2021 [monthly]
Recruiting NA
-
Oct 2020 — Jan 2021 [monthly]
Recruiting NA
-
Sep 2020 — Oct 2020 [monthly]
Recruiting NA
-
Aug 2020 — Sep 2020 [monthly]
Recruiting NA
-
Apr 2020 — Aug 2020 [monthly]
Recruiting NA
First recorded
Feb 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Lucid Diagnostics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .